- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05224778
DMCRN-02-001: Vurdering av pediatriske endepunkter i DM1 (ASPIRE-DM1)
Vurdering av pediatriske endepunkter i DM1 (ASPIRE-DM1)
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).
Previous studies have enrolled a very limited number of children with CDM.
The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Ruby Langeslay
- Telefonnummer: 804-828-8481
- E-post: ruby.langeslay@vcuhealth.org
Studer Kontakt Backup
- Navn: Jennifer Raymond
- Telefonnummer: 804-828-6318
- E-post: jennifer.raymond@vcuhealth.org
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- University of California, Los Angeles
-
Ta kontakt med:
- Merve Kaleli
- E-post: MKaleli@mednet.ucla.edu
-
Hovedetterforsker:
- Perry Shieh, MD, PhD
-
Ta kontakt med:
- Dennis Fernando
- Telefonnummer: 310-825-3264
- E-post: DeFernando@mednet.ucla.edu
-
-
Kansas
-
Fairway, Kansas, Forente stater, 66205
- Rekruttering
- University of Kansas Medical Center
-
Hovedetterforsker:
- Jeffrey Statland, MD
-
Ta kontakt med:
- Michaela Walker
- E-post: mwalker20@kumc.edu
-
Ta kontakt med:
- Cassidy Nelson
- E-post: cnelson15@kumc.edu
-
-
New York
-
Rochester, New York, Forente stater, 14642
- Rekruttering
- University of Rochester Medical Center
-
Ta kontakt med:
- Jim Hilbert
- E-post: james_hilbert@urmc.rochester.edu
-
Ta kontakt med:
- Jeanne Dekdebrun
- E-post: jeanne_dekdebrun@urmc.rochester.edu
-
Hovedetterforsker:
- Bohoon Lee, MD
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23298
- Rekruttering
- Virginia Commonwealth University
-
Ta kontakt med:
- Shantel Kyles
- E-post: shantel.brown@vcuhealth.org
-
Hovedetterforsker:
- Nicholas E. Johnson, MD
-
Ta kontakt med:
- Jodie Howell
- E-post: jodie.howell@vcuhealth.org
-
-
-
-
-
Milan, Italia, 20162
- Rekruttering
- Centro Clinico NeMO
-
Ta kontakt med:
- Michela Nani
- E-post: michela.nani@centrocliniconemo.it
-
Ta kontakt med:
- Luca Mauro
- E-post: luca.mauro@centrocliniconemo.it
-
Hovedetterforsker:
- Valeria Sansone, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
30 children with CDM
Beskrivelse
Inclusion Criteria:
- Age neonate to 3 years 11 months at enrollment.
- A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
- Guardian is willing and able to sign consent and follow study procedures
Exclusion Criteria:
- Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of the site investigator
- Significant trauma within one month
- Internal metal or devices (exclusion for DEXA component)
- History of bleeding disorder or platelet count <50,000
- History of reaction to local anesthetic
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Congenital Myotonic Dystrophy (CDM)
CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500). |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To evaluate motor milestone attainment in individuals with CDM and ChDM and compare to typically developing children
Tidsramme: Through study completion at 18 months
|
Milestone Assessment using Peabody definitions: This survey would ask parents to assess the age of motor milestones in days, months of infant age. Birth history, including prematurity, ventilatory status, and feeding problems would also be collected on the CRF. Feeding and ventilatory support, as well as height and weight will be collected at each study visit. |
Through study completion at 18 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Dysarthria Assessment
Tidsramme: Through study completion at 18 months
|
A blinded, standardized video assessment tabulating language milestones by a trained rater will be conducted at each visit. |
Through study completion at 18 months
|
|
Vineland
Tidsramme: Through study completion at 18 months
|
The Vineland will be administered by an interviewer to ensure standardized intake of data. This assessment will capture the adaptive function, including gross motor and fine motor, as reported by the parent proxy. |
Through study completion at 18 months
|
|
CCMDHI
Tidsramme: Through study completion at 18 months
|
The congenital and childhood myotonic dystrophy health index is a disease specific patient or proxy reported outcome measure specific to these conditions. The current study will utilize the proxy version. |
Through study completion at 18 months
|
|
Domain Delta
Tidsramme: Through study completion at 18 months
|
This assessment asks parents for global impression of change related to the baseline visit and will be used as an anchoring measure for the statistical analyses. |
Through study completion at 18 months
|
|
Gross Motor Function Measure (GMFM-88)
Tidsramme: Through study completion 18 months
|
The GMFM assesses functional abilities like lying/rolling, sitting, crawling/kneeling, standing, and walking, running, and jumping. |
Through study completion 18 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Correlate the functional outcome measures with potential biomarkers in CDM.
Tidsramme: Baseline
|
Fine needle muscle biopsy:On the baseline visit, a fine needle aspirate will be performed. Biopsy will only be peformed once to minimize the risk. The procedure will be performed with local anesthesia (1% lidocaine without epinephrine and free of preservatives) of the vastus lateralis. Following lidocaine injection, a fine needle will be used to aspirate the quadriceps muscle to obtain a total of one aspirate. The aspirate will be flash frozen in liquid nitrogen. A similar procedure has been performed on adults with DM1, and the average biopsy yields sufficient tissue for RNA-Seq analysis. |
Baseline
|
|
Blood Sampling
Tidsramme: Baseline, month 12, month 18
|
DNA and RNA samples will be processed by Virginia Commonwealth University. |
Baseline, month 12, month 18
|
|
Muscle mass, DEXA
Tidsramme: Baseline, month 12, month 18
|
Lean muscle mass will be evaluated using serial DEXA scans as an exploratory endpoint. All sites will use a Hologic DEXA scanner. Investigators will evaluate whole body lean mass, left and right arm lean mass, and left and right leg lean mass. Particularly early in childhood, investigators would expect rapid changes in lean muscle mass. If there were a divergence between controls and subjects with CDM, this would provide evidence that CDM is a disorder of muscle maturity, as well as provide a potential biomarker. |
Baseline, month 12, month 18
|
|
World Health Organization (WHO) Motor Milestones
Tidsramme: Through study completion at 18 months
|
The WHO Motor Milestones is a set of 6 standardized motor milestones that include 1) Sitting without support, 2) Standing with assistance, 3) Hands-&-knees crawling, 4) Walking with assistance, 5) Standing alone, and 6) Walking alone. |
Through study completion at 18 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Nicholas E. Johnson, MD, Virginia Commonwealth University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Muskel- og skjelettsykdommer
- Sykdommer i nervesystemet
- Muskelsykdommer
- Nevromuskulære sykdommer
- Genetiske sykdommer, medfødte
- Nevrodegenerative sykdommer
- Heredodegenerative lidelser, nervesystemet
- Muskellidelser, atrofisk
- Muskeldystrofier
- Myotoniske lidelser
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Myotonisk dystrofi
Andre studie-ID-numre
- HM20023386
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .